BRPI0516112A - métodos para neuroproteção - Google Patents
métodos para neuroproteçãoInfo
- Publication number
- BRPI0516112A BRPI0516112A BRPI0516112-6A BRPI0516112A BRPI0516112A BR PI0516112 A BRPI0516112 A BR PI0516112A BR PI0516112 A BRPI0516112 A BR PI0516112A BR PI0516112 A BRPI0516112 A BR PI0516112A
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- group
- phenyl
- alkyl
- methods
- Prior art date
Links
- 230000004112 neuroprotection Effects 0.000 title abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
Abstract
MéTODOS PARA NEUROPROTEçãO. A presente invenção é dirigida a métodos para prover neuroproteção compreendendo administrar a um indivíduo em necessidade do mesmo uma quantidade terapeuticamente efetiva de um composto selecionado dentre o grupo consistindo de Fórmula (I) e Fórmula (Il), ou um sal farmaceuticamente aceitável ou éster do mesmo: Fórmula (I) Fórmula (Il) em que fenila é substituída a X com um a cinco átomos de halogênio selecionados dentre o grupo consistindo de flúor, cloro, bromo e iodo; e, R~ 1'~ R~ 2'~, R~ 3'~, R~ 4'~, R~ 5'~ e R~ 6'~ são independentemente selecionados dentre o grupo consistindo de hidrogênio e C~ 1~-C~ 4~ alquila; em que C~ 1~-C~ 4~ alquila é opcionalmente substituída com fenila (em que fenila é opcionalmente substituída com substituintes independentemente selecionados dentre o grupo consistindo de halogênio, C~ 1~-C~ 4~ alquila, C~ 1~,-C~ 4~ alcóxi, amino, nitro e ciano).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61940204P | 2004-10-15 | 2004-10-15 | |
| US69840305P | 2005-07-12 | 2005-07-12 | |
| PCT/US2005/036695 WO2006044472A1 (en) | 2004-10-15 | 2005-10-14 | Carbamate compounds for use in treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0516112A true BRPI0516112A (pt) | 2008-08-26 |
Family
ID=35840528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0516112-6A BRPI0516112A (pt) | 2004-10-15 | 2005-10-14 | métodos para neuroproteção |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1802294A1 (pt) |
| JP (1) | JP2008516961A (pt) |
| KR (3) | KR20110049901A (pt) |
| AU (1) | AU2005295787A1 (pt) |
| BR (1) | BRPI0516112A (pt) |
| CA (1) | CA2584854A1 (pt) |
| EA (1) | EA200700871A1 (pt) |
| EC (1) | ECSP077395A (pt) |
| IL (1) | IL182432A0 (pt) |
| MX (1) | MX2007004491A (pt) |
| NI (1) | NI200700094A (pt) |
| NO (1) | NO20072444L (pt) |
| SG (1) | SG142306A1 (pt) |
| WO (1) | WO2006044472A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| KR20190081385A (ko) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| FR3110393B1 (fr) * | 2020-05-20 | 2022-05-06 | Grn Consulting | Compose et composition pour induire une neuroprotection |
| JP2023539291A (ja) * | 2020-08-31 | 2023-09-13 | バイオ－ファーム ソリューションズ カンパニー リミテッド | 神経変性疾患の予防又は治療用フェニルアルキルカルバメート化合物 |
| KR20230051206A (ko) | 2020-09-10 | 2023-04-17 | (주)바이오팜솔루션즈 | 정신질환 치료 또는 완화용 설파메이트 유도체 화합물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010034365A1 (en) * | 1996-01-16 | 2001-10-25 | Choi Yong Moon | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| PL213323B1 (pl) * | 1999-08-20 | 2013-02-28 | Ortho Mcneil Pharm Inc | Kompozycja farmaceutyczna i jej zastosowanie |
| PL364680A1 (en) * | 2001-02-27 | 2004-12-13 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| CA2580640A1 (en) * | 2004-09-16 | 2006-03-30 | Janssen Pharmaceutica N.V. | Methods of treating epileptogensis and epilepsy |
-
2005
- 2005-10-14 MX MX2007004491A patent/MX2007004491A/es unknown
- 2005-10-14 WO PCT/US2005/036695 patent/WO2006044472A1/en not_active Ceased
- 2005-10-14 JP JP2007536843A patent/JP2008516961A/ja active Pending
- 2005-10-14 EP EP05810159A patent/EP1802294A1/en not_active Withdrawn
- 2005-10-14 KR KR1020117007395A patent/KR20110049901A/ko not_active Ceased
- 2005-10-14 AU AU2005295787A patent/AU2005295787A1/en not_active Abandoned
- 2005-10-14 KR KR1020097019737A patent/KR20090130175A/ko not_active Ceased
- 2005-10-14 CA CA002584854A patent/CA2584854A1/en not_active Abandoned
- 2005-10-14 KR KR1020077010744A patent/KR20070085309A/ko not_active Ceased
- 2005-10-14 NI NI200700094A patent/NI200700094A/es unknown
- 2005-10-14 EA EA200700871A patent/EA200700871A1/ru unknown
- 2005-10-14 SG SG200802877-1A patent/SG142306A1/en unknown
- 2005-10-14 BR BRPI0516112-6A patent/BRPI0516112A/pt not_active IP Right Cessation
-
2007
- 2007-04-10 IL IL182432A patent/IL182432A0/en unknown
- 2007-04-13 EC EC2007007395A patent/ECSP077395A/es unknown
- 2007-05-11 NO NO20072444A patent/NO20072444L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090130175A (ko) | 2009-12-18 |
| EP1802294A1 (en) | 2007-07-04 |
| SG142306A1 (en) | 2008-05-28 |
| NI200700094A (es) | 2008-02-11 |
| NO20072444L (no) | 2007-06-14 |
| ECSP077395A (es) | 2007-05-30 |
| CA2584854A1 (en) | 2006-04-27 |
| KR20110049901A (ko) | 2011-05-12 |
| WO2006044472A1 (en) | 2006-04-27 |
| MX2007004491A (es) | 2007-08-08 |
| KR20070085309A (ko) | 2007-08-27 |
| EA200700871A1 (ru) | 2007-10-26 |
| IL182432A0 (en) | 2007-09-20 |
| JP2008516961A (ja) | 2008-05-22 |
| AU2005295787A1 (en) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI200800008A (es) | Métodos para la neuroprotección | |
| NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
| CO5570670A2 (es) | Pulmonar obstructiva cronica | |
| ECSP088172A (es) | Metodos para tratar la epileptogenesis | |
| BR0207831A (pt) | Compostos carbamato para uso na prevenção ou tratamento de distúrbios do movimento | |
| BRPI0518068A (pt) | composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada | |
| BR0207645A (pt) | Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos | |
| BR0207644A (pt) | Compostos de carbamato para uso na prevenção ou no tratamento de distúrbio bipolar | |
| BRPI0606484A2 (pt) | métodos para controle do intervalo qt | |
| BR0207830A (pt) | Compostos de carbamato para uso em prevenir ou tratar distúrbios de ansiedade | |
| BR0207673A (pt) | Compostos de carbamato para o uso no tratamento de dor | |
| ECSP077395A (es) | Compuesto de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos | |
| BR0207829A (pt) | Composto de carbamato para uso na prevenção ou tratamento de distúrbios psicóticos | |
| ATE538784T1 (de) | Verfahren zur behandlung von substanzbedingten erkrankungen | |
| CO6180505A2 (es) | Metodos para el tratamiento de transtornos cocleares y vestibulares | |
| CO6160292A2 (es) | Metodos de tratamiento de transtornos de comportamiento perturbador 877 | |
| TW200701978A (en) | Methods of treating epileptogenesis and epilepsy | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| CY1110672T1 (el) | Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2213 DE 04/06/2013. |